BioCentury | Nov 23, 2009
Company News

Metris B.V., Porsolt & Partners Pharmacology SAS sales and marketing update

...co-market Metris' Laboras in vivo screening technology for preclinical compounds. Financial terms were not disclosed. Metris...
BioCentury | Aug 27, 2007
Strategy

Exubera not accreting

The Incretin Movement Exubera not accreting While the new incretin-based additions to the Type II diabetes arsenal eclipsed half a billion dollars in sales in the first half of 2007, not all recent entrants to...
BioCentury | Jun 4, 2007
Tools & Techniques

Signal snapshots

Mass spectrometry-based proteomics can reveal protein-protein interactions using large sample sizes and analyzing binding relationships long after a cell signal has started. But it has been difficult to parse the molecular events as they occur...
BioCentury | Jul 3, 2006
Company News

Metris, Plethora deal

...channel blocker, to start Phase I/II testing to treat endometriosis. Metris is eligible for royalties. Metris Therapeutics Ltd....
BioCentury | Aug 12, 2002
Company News

Metris, J&J deal

...exclusive worldwide license to an undisclosed preclinical compound from Janssen Pharmaceutica, a subsidiary of JNJ. Metris...
...and commercialization milestones to Metris plus royalties in sales. If the option is not exercised Metris...
...exclusive rights to develop and commercialize the compound and will pay Janssen milestones and royalties. Metris...
BioCentury | Aug 7, 2002
Company News

Metris licenses a JNJ compound

...an exclusive worldwide license to an undisclosed preclinical oncology compound from Johnson & Johnson (JNJ). Metris...
...if exercised, would pay Metris milestones and royalties. If JNJ does not exercise the option, Metris...
BioCentury | Jul 15, 2002
Company News

Antisoma board of directors update

Antisoma plc (LSE:ASM; NASD-EU:ASOM), London, U.K. Business: Cancer Appointed: Ann Hacker, CEO of Metris Therapeutics Ltd. WIR Staff cancer...
BioCentury | Jul 20, 2000
Financial News

Metris raises $16.49 million in private equity

...Metris Therapeutics (Wokingham, U.K.) raised 11 million ($16.49 million) through a private equity financing. Metris...
Items per page:
1 - 8 of 8
BioCentury | Nov 23, 2009
Company News

Metris B.V., Porsolt & Partners Pharmacology SAS sales and marketing update

...co-market Metris' Laboras in vivo screening technology for preclinical compounds. Financial terms were not disclosed. Metris...
BioCentury | Aug 27, 2007
Strategy

Exubera not accreting

The Incretin Movement Exubera not accreting While the new incretin-based additions to the Type II diabetes arsenal eclipsed half a billion dollars in sales in the first half of 2007, not all recent entrants to...
BioCentury | Jun 4, 2007
Tools & Techniques

Signal snapshots

Mass spectrometry-based proteomics can reveal protein-protein interactions using large sample sizes and analyzing binding relationships long after a cell signal has started. But it has been difficult to parse the molecular events as they occur...
BioCentury | Jul 3, 2006
Company News

Metris, Plethora deal

...channel blocker, to start Phase I/II testing to treat endometriosis. Metris is eligible for royalties. Metris Therapeutics Ltd....
BioCentury | Aug 12, 2002
Company News

Metris, J&J deal

...exclusive worldwide license to an undisclosed preclinical compound from Janssen Pharmaceutica, a subsidiary of JNJ. Metris...
...and commercialization milestones to Metris plus royalties in sales. If the option is not exercised Metris...
...exclusive rights to develop and commercialize the compound and will pay Janssen milestones and royalties. Metris...
BioCentury | Aug 7, 2002
Company News

Metris licenses a JNJ compound

...an exclusive worldwide license to an undisclosed preclinical oncology compound from Johnson & Johnson (JNJ). Metris...
...if exercised, would pay Metris milestones and royalties. If JNJ does not exercise the option, Metris...
BioCentury | Jul 15, 2002
Company News

Antisoma board of directors update

Antisoma plc (LSE:ASM; NASD-EU:ASOM), London, U.K. Business: Cancer Appointed: Ann Hacker, CEO of Metris Therapeutics Ltd. WIR Staff cancer...
BioCentury | Jul 20, 2000
Financial News

Metris raises $16.49 million in private equity

...Metris Therapeutics (Wokingham, U.K.) raised 11 million ($16.49 million) through a private equity financing. Metris...
Items per page:
1 - 8 of 8